We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Enzo Biochem
An SI Board Since July 1996
Posts SubjectMarks Bans
83 3 0
Emcee:  joe blow23 Type:  Unmoderated
VANCOUVER, Canada--(BUSINESS WIRE)--July 10, 1996--Enzo Biochem (ASE:ENZ) of Famingdale, N.Y.
announced today that its scientists and collaborators have produced human immune cells that are completely and stably
resistant to multiple challenges of HIV.

This approach is targeted to provide the medical community with a powerful new weapon in the fight against AIDS.
The Company said that following completion of the preclinical studies, it plans to move ahead towards the development
of protocols for human clinical studies.

These findings were released today at the 11th International Conference on AIDS in a presentation by Norman Kelker,
Ph.D., Senior Vice President of Enzo and a participating scientist at the conference. The studies show that CD4+ cells,
that are normally sensitive to HIV-1 infection, are protected when treated with Enzo's antisense construct. Resistance
to HIV-1, which was shown to correlate with production of antisense RNA by the cells, could lead to restoring
immune competence in patients, even in the presence of challenge by HIV.

"We have now successfully demonstrated that we can create CD4+ cells that are resistant to HIV-1 and that maintain
their resistance to the virus over a prolonged period," said Dr. Kelker. "This is a very important step in moving
towards the development of an effective clinical product for HIV therapy. We believe that our antisense therapy alone,
or in combination with already established protocols, can become an effective and widely applied treatment for
HIV-infected individuals."

Enzo's approach utilizes methods to overcome effects due to the variability and mutability of the virus and to localize
the antisense in the cell nucleus where its antiviral activity is most effective. The Company noted that, unlike currently
used treatments aimed at viral reverse transcriptase or protease, its antisense approach is designed not to require
repeated applications.

According to the report, which presents results from a more than year-long study, Enzo's therapeutic approach is
aimed at inhibiting expression of HIV-1 genes by antisense RNA. The approach is gene specific and does not affect
cellular genes. Thus, the establishment of such antisense-producing immune cells in the patient could protect against
collapse of the immune system in AIDS patients. The therapy would be applied to immune cells removed from the
patient and altered ex vivo, that is, outside the body, by the introduction of antisense producing genes. Altered cells
reimplanted in the patient are expected to propagate HIV-resistant immune cells.

Enzo Biochem is engaged in the research, development and manufacture of innovative health care products based on
molecular biology and genetic engineering techniques, and in providing diagnostic services to the medical community.

CONTACT: Barry Weiner, 212/856-0876
Steve Anreder, 212/421-4020
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
83Does anybody anymore follow Enzo? Except me? A lot of things are going to hapAUGUSTIN-February 9
82Does look like the old management it is in its way out. I hope so. Too many prAUGUSTIN-4/14/2019
81 This company has had to many broken promisses with the the diagnostic dealLumpsum-5/26/1997
80 Anyone still there?<eom>Preston Lurie-5/22/1997
79 Dennis this stock is shklsdjf;ttt. If it were owned buy any mutual funds they wLumpsum-4/24/1997
78 Help me! I'm melting! According to past history, we should be buying at thiDennis Dengler-3/25/1997
77 Any news on this stock it has been a dogLumpsum-3/17/1997\/research/enzo/enzo.htm Look at the MH Meyerson home page to readLumpsum-2/9/1997
75 Meyerson had issued a previous 'Strong Buy' on Enzo Biochem 6 months toLarry Laskos-1/31/1997
74 Any comments on this release????? What connection does this firm have to ENZO aSteve-1/31/1997
73 I have held Enzo for 1 year.........and trying to be patient! In the meanwhile,Steve-1/30/1997
72 The announcement of partnership with Abbott is not to be made before February olen kay-1/30/1997
71 Jerry Wenger update from Friday's radio show. Jerry said he called his invRich-1/19/1997
70 Thanks again Rich, got to wonder why Jerry would sell any of his Enzo shares ifDoug Robinson-1/16/1997
69 Jerry Wenger Update Jerry Wenger said he was not able to talk to the investmenRich-1/16/1997
68 Kenneth; Wasn't the earning you are referring to reported in December? UnlSteve Lokness-1/16/1997
67 Hey Jack, the key with successful investing based on the J. Wenger Shows is to Kenneth Munson-1/16/1997
66 Earnings were expected to be @.04; they came in at a disappointing .01. The priKenneth Munson-1/16/1997
65 Aaron take a look at Rich's message. Maybe the bride and groom haven'tDoug Robinson-1/15/1997
64 Thanks again Rich, looks like the stock will probably make a move upwards tomorDoug Robinson-1/15/1997
63 Jerry Wenger said that Enzo is going to a meeting at Morgan Stanley tomorrow. Rich-1/15/1997
62 Doug, Thanks for your post, I too received a call from a Broad Street broker iAARON DIDICH-1/15/1997
61 Rich, thanks for the reply. Interesting source regarding the info. I got a caDoug Robinson-1/15/1997
60 To all interested parties im not very happy since my jan 20 calls are about to jack rosenberg-1/14/1997
59 Jerry didn't have too much to say about ENZ tonight. He just said that theRich-1/14/1997
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):